BSE filing, NSE: AAREYDRUGS. Summary written from the filing by ALFA Finder's alert engine.
Aarey Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹109.60
- Market cap
- ₹310.8 Cr
- Revenue (annual)
- ₹472.3 Cr
- Net profit (annual)
- ₹3.97 Cr
- P/E (TTM)
- 74.4×Sector 46.5×
- Promoter holding
- 41.45%+3.74% QoQ
- FII holding
- 4.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarey Drugs & Pharmaceuticals Ltd
All →Aarey Drugs & Pharmaceuticals Capital Structure Change
Aarey Drugs approved allotment of 1,150,000 equity shares from warrant conversion at ₹47.85 each, receiving ₹5.50 Crore. Issued capital rises to 31,874,303 shares.
- Value
- ₹5.50 Cr
Aarey Drugs & Pharmaceuticals Capital Structure Change
Promoter and promoter group of Aarey Drugs & Pharmaceuticals Ltd acquired 23.70 lakh shares following the conversion of warrants. The acquisition increased their stake by 4.81%.
- Promoter stake change
- +4.81%
Aarey Drugs & Pharmaceuticals Capital Structure Change
Aarey Drugs allotted equity shares to promoters following the conversion of 23,40,000 warrants. This capital structure change increases the promoters' equity stake in the company.
- Value
- ₹11.20 Cr
Aarey Drugs & Pharmaceuticals Annual General Meeting
Aarey Drugs & Pharmaceuticals Ltd. held its 36th Annual General Meeting on September 30, 2026, to conduct business including financial statement adoption and director re-appointment.
Aarey Drugs & Pharmaceuticals Capital Structure Change
Aarey Drugs & Pharmaceuticals Ltd approved the allotment of 11,50,000 equity shares following the conversion of warrants. The allotment aggregate value is Rs. 7.34 Crore.
- Value
- ₹7.34 Cr
Aarey Drugs & Pharmaceuticals Other Announcement
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern. This is a routine regulatory compliance disclosure regarding the company's equity distribution.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.